肿瘤细胞治疗研究
英文原题:AI-assisted image analysis of tumor-infiltrating lymphocytes as a prognostic marker in chemotherapy-naïve luminal breast cancer.
AI-assisted image analysis of tumor-infiltrating lymphocytes as a prognostic marker in chemotherapy-naïve luminal breast cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在三阴性和HER2阳性乳腺癌中,TIL(肿瘤浸润淋巴细胞)已被确立为预测及预后生物标志物,但其在腔面亚型中的作用尚不明确。
我们在DBCG99c队列中,利用基于人工智能的图像分析评估2298例按PAM50分型的腔面型乳腺癌患者TIL的预后意义。采用商业平台自动定量间质(sTIL)和上皮内(iTIL)TIL密度。间质TIL浸润较高与总生存期改善相关,尤其是在前5年内(异质性p=0.01)。多变量模型中,较高sTIL独立预测远处复发或任何复发风险较低(sHR=0.95,95% CI:0.91–0.99)及生存改善(早期HR=0.91,95% CI:0.85–0.97;晚期HR=0.99,95% CI:0.97–1.00)。上皮内TIL不具有预后意义。不同分子亚型、淋巴结状态或肿瘤分级之间均未观察到显著交互作用,但腔面B型肿瘤中iTIL效应较强呈非显著趋势。
因此,基于人工智能的TIL定量可为高危腔面型乳腺癌提供独立预后信息。
In triple-negative and HER2-positive breast cancer, tumor-infiltrating lymphocytes (TILs) are established predictive and prognostic biomarkers, but their role in luminal subtypes remains unclear.
We investigated the prognostic significance of TILs using AI-based image analysis in 2298 luminal breast cancers from the DBCG99c cohort, classified by PAM50. Stromal (sTIL) and intraepithelial (iTIL) densities were quantified automatically using a commercial platform. Higher stromal TIL infiltration was associated with improved overall survival, particularly within the first 5 years (heterogeneity p = 0. 01). In multivariable models, higher sTILs independently predicted lower risk of distant or any recurrence (sHR = 0.
95, 95% CI 0. 91-0. 99) and improved survival (HR = 0. 91, 95% CI 0. 85-0. 97 early; HR = 0. 99, 95% CI 0. 97-1. 00 late). Intraepithelial TILs were not prognostic. No significant interactions were observed by molecular subtype, nodal status, or grade, although a nonsignificant trend toward stronger iTIL effects appeared in luminal B tumors. AI-based TIL quantification thus provides independent prognostic information in high-risk luminal breast cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。